Advertisment
|
|
|
news roundup
A recent survey by Worldwide Clinical Trials showed coordinators are concerned that eCOA interferes with normal patient rapport.
Nonclinical models are limited, and clinical trials are challenging because, among many factors, is that pain is subjective, making it hard to define objective endpoints or to compare one drug to another.
R&G Pharma Studies, a Beijing, China-based CRO, has broadened its adoption of Medidata's Clinical Cloud, becoming the first Chinese customer to use Medidata CTMS.
Synexus owns 25 research sites in 10 countries. The addition of RAA’s sites will give it greater capacity, particular U.S. market expertise and therapeutic experience.
|
|
|
Subscribe
|
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
Advertisment
|
|
|
RBM
Properly identifying risks upfront enables study teams to obtain a better perspective on how study execution and site operations intertwine.
EPS, a CRO based in Tokyo, Japan, has chosen Bioclinica’s COMPASS technology and professional services as its risk-based monitoring (RBM) solution for clinical trials in Japan.
A look at technology, plans, roles and more for a simple solution to RBM.
This eBook includes the latest issues that have risen to prominence as RBM adoption grows.
|
|
|
Articles
By better understanding the wants and needs of site staff, sponsor-driven support and training can be tailored for enhanced trial success.
|
|
Blog Posts
Last week was a big week of meetings in the Netherlands for clinical trials and adaptive pathways in the EU.
|
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
